Is VIR a good stock to buy? We came across a bullish thesis on Vir Biotechnology, Inc. on Valueinvestorsclub.com by Bohr. In this article, we will summarize the bulls’ thesis on VIR. Vir Biotechnology, Inc.’s share was trading at $9.19 as of May 25th. VIR’s trailing P/E was 5.92 according to Yahoo Finance.
Pressmaster/Shutterstock.com
Vir Biotechnology, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapeutic products to treat and prevent serious infectious diseases in the United States and internationally. VIR is positioning itself as a potentially disruptive player in metastatic castration-resistant prostate cancer (mCRPC), an advanced and difficult-to-treat stage of prostate cancer with a five-year survival rate of roughly 30%. The company’s lead asset, VIR-5500, is a PSMA-targeted T-cell engager designed to direct T-cells toward prostate cancer cells while minimizing the systemic toxicity that has limited competing therapies.
Read More: 15 AI Stocks That Are Quietly Making Investors Rich
Read More: Undervalued AI Stock Poised For Massive Gains: 10000% Upside Potential
Its differentiated “PRO-XTEN” masking technology keeps the drug inactive in circulation and activates it only at tumor sites, potentially reducing cytokine release syndrome while allowing higher and more effective dosing. Updated Phase 1 data has reinforced the bullish thesis, with no dose-limiting toxicities observed and cytokine release syndrome largely limited to manageable grade 1 events. In the highest dose cohorts, VIR-5500 achieved PSA50 responses in 82% of patients, PSA90 responses in 53%, and a 45% objective response rate, comparing favorably against competitors such as Janux, Regeneron, and Johnson & Johnson.
The significantly higher PSA90 response rate versus Janux suggests deeper remissions may be achievable due to the therapy’s improved safety profile. Vir Biotechnology further strengthened its position through a major strategic collaboration with Astellas Pharma worth up to $1.7 billion, including a premium equity investment that validates confidence in VIR-5500 as a possible successor to Xtandi as patent expirations approach.
With nearly $950 million in pro forma cash against a roughly $1.4 billion market capitalization, the market is valuing the platform at less than $500 million. Positive expansion cohort data expected in Q2 2026 could drive a rerating toward $2 billion or more, while a future acquisition by Astellas remains a plausible upside scenario.
Previously, we covered a bullish thesis on CRISPR Therapeutics AG (CRSP) by MADD-Scientis in March 2025, which highlighted Casgevy commercialization, strong gene-editing pipeline optionality, and reimbursement-driven upside in curative therapies. CRSP’s stock price has appreciated by approximately 22.91% since our coverage. Bohr shares a similar view but emphasizes Vir Biotechnology, Inc. (VIR) and its mCRPC T-cell engager VIR-5500, focusing more on early clinical efficacy signals and long-term commercialization trajectory.